Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

Delayed Trp53 Activation Protects Dnmt3a -Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Ludovica Marando, George Giotopoulos, Pedro Madrigal, Dhoyazan M A Azazi, Ryan Asby, Maria Erendira Calleja-Cervantes, David Lara-Astiaso, Nicola K. Wilson, Rebecca Hannah, Jaana Bagri, Elsa Barnard, Sarah J Horton, Berthold Gottgens, Elli Papaemmanuil, Shuchi Agrawal Singh, Malgorzata Gozdecka, George S Vassiliou, Brian J P Huntly

Blood (2024) 144 (Supplement 1): 190.

https://doi.org/10.1182/blood-2024-201612

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations

Blood (2024) 144 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2024-202688

Published: 2024

Journal Articles

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

Talha Badar, Terra L Lasho, Yael Kusne, Ludovica Marando, Abhishek A Mangaonkar, Christy M Finke, James M. Foran, Aref Al-Kali, Hassan Alkhateeb, Naseema Gangat, Rong He, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2023-187310

Published: 2023

Journal Articles

Machine Learning for Identification of High-Risk Clonal Haematopoiesis Using Blood Count Data

William G Dunn, Isabella Withnell, Muxin Gu, Pedro Quiros, Sruthi Cheloor Kovilakam, Ludovica Marando, Margarete Fabre, Irina Mohorianu, Dragana Vuckovic, George Vassiliou

Blood (2023) 142 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2023-184721

Published: 2023

Journal Articles

Prevalence and significance of DDX41 gene variants in the general population

Sruthi Cheloor Kovilakam, Muxin Gu, William G. Dunn, Ludovica Marando, Clea Barcena, Serena Nik-Zainal, Irina Mohorianu, Siddhartha P. Kar, Margarete A. Fabre, Pedro M. Quiros, George S. Vassiliou

Blood (2023) 142 (14): 1185–1192.

https://doi.org/10.1182/blood.2023020209

Published: 2023

Includes: Supplemental data

Journal Articles

Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction

Haiyang Yun, PhD, Shabana Vohra, PhD, Annalisa Mupo, PhD, George Giotopoulos, PhD, Daniel Sasca, MD, Sarah J. Horton, PhD, Shuchi Agrawal-Singh, PhD, Eshwar Meduri, PhD, Faisal Basheer, MBBChir, MA, PhD, Ludovica Marando, Malgorzata Gozdecka, PhD, Oliver M. Dovey, PhD, Xiaonan Wang, PhD, Paolo Gallipoli, PhD, Cameron Osborne, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath

Blood (2019) 134 (Supplement_1): 278.

https://doi.org/10.1182/blood-2019-122413

Published: 2019

Journal Articles

Glutaminolysis is a metabolic dependency in FLT3 ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition

Paolo Gallipoli, George Giotopoulos, Konstantinos Tzelepis, Ana S. H. Costa, Shabana Vohra, Paula Medina-Perez, Faisal Basheer, Ludovica Marando, Lorena Di Lisio, Joao M. L. Dias, Haiyang Yun, Daniel Sasca, Sarah J. Horton, George Vassiliou, Christian Frezza, Brian J. P. Huntly

Blood (2018) 131 (15): 1639–1653.

https://doi.org/10.1182/blood-2017-12-820035

Published: 2018

Includes: Supplemental data

Journal Articles

From Renal Siderosis Due to Perpetual Hemosiderinuria to Possible Liver Overload Due to Extravascular Hemolysis: Changes in Iron Metabolism in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients On Eculizumab.

Antonio M. Risitano, MD, PhD, Elisa Seneca, Ludovica Marando, Massimo Imbriaco, Ernesto Soscia, Francesca Soscia, Laura Micol Pizzuti, Luca Malcovati, Susanna Fenu, Anna Paola Iori, Rosario Notaro, M.D., Margherita Matarazzo, Bruno Rotoli

Blood (2009) 114 (22): 4031.

https://doi.org/10.1182/blood.V114.22.4031.4031

Published: 2009

Journal Articles

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Blood (2009) 113 (17): 4094–4100.

https://doi.org/10.1182/blood-2008-11-189944

Published: 2009

Journal Articles

Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA

Antonio M. Risitano, MD, PhD, Elisa Seneca, Ludovica Marando, Bianca Serio, Carmine Selleri, Giulia Scalia, Luigi Del Vecchio, MD, Annapaola Iori, M.D., Alexander Kulagin, Sebastien Maury, Joerg Halter, Vikas Gupta, MD, MRCP, MRCPath, Andrea Bacigalupo, MD, Gerard Socié, Andre Tichelli, Judith Marsh, Hubert Schrezenmeier, Jakob R. Passweg, MD, MS, Bruno Rotoli

Blood (2008) 112 (11): 1042.

https://doi.org/10.1182/blood.V112.11.1042.1042

Published: 2008

Journal Articles

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Blood (2008) 112 (11): 485.

https://doi.org/10.1182/blood.V112.11.485.485

Published: 2008

Journal Articles

Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab

Antonio M. Risitano, Ludovica Marando, Elisa Seneca, Bruno Rotoli

Blood (2008) 112 (2): 449–451.

https://doi.org/10.1182/blood-2008-04-151613

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

Antonio M. Risitano, MD, PhD, Carmine Selleri, MD, Bianca Serio, MD, Ludovica Marando, Andrea Camera, MD, Lucio Catalano, MD, Giulia Scalia, PhD, Luigi Del Vecchio, MD, Bruno Rotoli, MD

Blood (2007) 110 (11): 1692.

https://doi.org/10.1182/blood.V110.11.1692.1692

Published: 2007

NARROW

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Delayed Trp53 Activation Protects Dnmt3a -Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

Machine Learning for Identification of High-Risk Clonal Haematopoiesis Using Blood Count Data

Prevalence and significance of DDX41 gene variants in the general population

Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction

Glutaminolysis is a metabolic dependency in FLT3 ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition

From Renal Siderosis Due to Perpetual Hemosiderinuria to Possible Liver Overload Due to Extravascular Hemolysis: Changes in Iron Metabolism in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients On Eculizumab.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only